Skip to main content

Ormalvi Disease Interactions

There are 9 disease interactions with Ormalvi (dichlorphenamide).

Major

Dichlorphenamide (applies to Ormalvi) acidosis

Major Potential Hazard, Moderate plausibility.

The use of dichlorphenamide is contraindicated acidotic patients (hyperchloremic or respiratory).

Major

Dichlorphenamide (applies to Ormalvi) adrenocortical insufficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency

The use of dichlorphenamide is contraindicated in adrenocortical insufficiency.

Major

Dichlorphenamide (applies to Ormalvi) dehydration

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypokalemia, Hyponatremia

The use of dichlorphenamide is contraindicated in patients with hyponatremia or hypokalemia, or in conditions in which serum levels of sodium or potassium are depressed.

Major

Dichlorphenamide (applies to Ormalvi) hepatic disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of dichlorphenamide is contraindicated in hepatic insufficiency.

Major

Dichlorphenamide (applies to Ormalvi) pulmonary disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

Dichlorphenamide should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation as their acidosis may be increased.

Major

Dichlorphenamide (applies to Ormalvi) renal dysfunction

Major Potential Hazard, Moderate plausibility.

The use of dichlorphenamide is contraindicated in renal failure.

Moderate

Carbonic anhydr. inhibitors (applies to Ormalvi) respiratory acidosis

Moderate Potential Hazard, Low plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.

Moderate

Carbonic anhydrase inhibitors (applies to Ormalvi) diabetes mellitus

Moderate Potential Hazard, Low plausibility.

Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.

Moderate

Carbonic anhydrase inhibitors (applies to Ormalvi) gout

Moderate Potential Hazard, Moderate plausibility.

Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.

Switch to professional interaction data

Ormalvi drug interactions

There are 230 drug interactions with Ormalvi (dichlorphenamide).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer